How Can We Effectively Combat Antibiotic Resistant Bacterial Pathogens?

The next pandemic seems likely to result from a bacterial pathogen. In this video, ANDREAS PESCHEL explores how we can effectively fight bacterial pathogens, especially where they are resistant to antibiotics. Adopting an interdisciplinary approach with colleagues from computational, clinical and compound focused sciences, Peschel’s research focuses on the bacteria Staphylococcus aureus commonly found in the human nose. Metagenome sequencing of the microbiome shows that an absence of Staphylococcus aureus often goes in tandem with the presence of Staphylococcus lugdunensis. With the latter seeming to effectively prevent a potentially deadly pathogen colonizing the microbiome, Peschel’s research breaks new ground in the development of a new kind of smart antibiotic.

DOI:

https://doi.org/10.21036/LTPUB10921

Cluster of Excellence “Controlling Microbes to Fight Infections” (CMFI), University of Tübingen

The surfaces of the human body host colonies of microorganisms, known as microbiomes. Along with bacteria which have a positive effect on human health, microbiomes contain potentially life-threatening pathogens. In the past, broad-spectrum antibiotics have often been used to tackle them. Nowadays it is known that this not only promotes resistance to antibiotics – in many cases it also damages the microbiome as a whole. A worldwide increase in antibiotic-resistant bacterial pathogens (ARBPs), coupled with declining discoveries of novel classes of antibiotics, raises the specter of a post-antibiotic era. Preventing the spread, human colonization, and subsequent infection by ARBPs is essential in preserving fundamental medical achievements of the 20th century. A paradigm shift in infection control is needed, putting a hold to the indiscriminate use of antibiotics and enabling the development of targeted anti-infective strategies that promote microbiome integrity. The researchers of the Cluster of Excellence "Controlling Microbes to Fight Infections" (CMFI) at the University of Tübingen aim to elucidate the mechanisms of interaction between beneficial and harmful bacteria in order to make them useful for targeted therapeutic interventions.